ArriVent BioPharma (AVBP) Q1 2025 earnings summary

Executive summary

• Clinical-stage biopharma advanced firmonertinib in pivotal Phase 3 trials for EGFR-mutant NSCLC and expanded its pipeline with ARR-217, a CDH17-targeted ADC, through a major license agreement.

• Completed enrollment in global Phase 3 study for firmonertinib in first-line NSCLC with EGFR exon 20 insertion mutations.

• Submitted first IND for ARR-217 in China, expanding the pipeline into gastrointestinal cancers.

• Cash, cash equivalents, and marketable securities totaled $205.5 million as of March 31, 2025, expected to fund operations for at least 12 months.

• Appointed Merdad Parsey, M.D., Ph.D., to the Board of Directors, adding significant industry experience.

Financial highlights

• Q1 2025 net loss was $64.4 million, up from $17.4 million in Q1 2024, driven by higher R&D expenses and a $40 million upfront payment for ARR-217.

• R&D expenses rose to $61.3 million from $17.0 million year-over-year, mainly due to the Lepu Biopharma payment and increased clinical activity.

• General and administrative expenses increased to $5.5 million from $3.7 million, reflecting public company infrastructure expansion.

• Net cash used in operations was $68.0 million for Q1 2025.

• Interest and investment income was $2.4 million, down from $3.3 million, due to lower invested balances.

Outlook and guidance

• Topline data from the pivotal Phase 3 firmonertinib study in first-line NSCLC with EGFR exon 20 insertion mutations expected in 2025.

• Update on development plans for firmonertinib in first-line NSCLC with EGFR PACC mutations anticipated in Q2 2025.

• ARR-217 expected to enter the clinic, initially targeting gastrointestinal cancers.

• Management expects continued operating losses as R&D and clinical trial investments increase, with no product revenue anticipated in the near term.

• Existing cash and marketable securities are projected to support operations through at least the next 12 months.